Emmaus Life Sciences has entered into a licensing and exclusive distribution agreement with NeoImmuneTech (NIT) for Endari, a ...

Johnson & Johnson (J&J) has completed its acquisition of Halda Therapeutics, a clinical-stage biotechnology company, for ...

Genmab is discontinuing development of acasunlimab after a pipeline review, pivoting focus to other oncology antibodies.

Data indicating unequal treatment effects in women has prompted calls for more nuance in Alzheimer’s diagnosis and drug ...

Sanofi has agreed to acquire hepatitis B vaccine manufacturer Dynavax for an equity value of around $2.2bn, bolstering the ...

Maryland’s Prescription Drug Affordability Board (PDAB) serves as a bellwether for how other states may address high drug ...

Innovent Biologics has received China’s NMPA approval for the NDA for Tabosun, a CTLA-4 monoclonal antibody for colon cancer.

Updated versions of best-selling drugs may mitigate some of the impact of patent cliff losses, but strategy is key in a ...

AstraZeneca's Andexxa will no longer be sold or manufactured in the US following FDA concerns around the drug's association ...

Shares rose 5% for Novo Nordisk on the approval of oral Wegovy as it looks to ease market pressures with a significant ...

The Amicus acquisition will bolster BioMarin’s rare disease portfolio, while potentially growing the company’s future revenue ...

Gilead Sciences has signed an agreement to acquire Repare Therapeutics’ polymerase theta (Polθ) ATPase inhibitor, RP-3467.